June 28, 2012 - 11:06 am
Posted in Featured
0 Comments
The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) had a significant impact on the treatment plans of oncologists and hematologists in attendance. According to a post-event survey conducted by Encuity Research, 76% of physicians in attendance indicated they are likely to change their patient treatment plans.
New breast cancer and prostate cancer treatment plans gained the most traction. Among the ASCO-attending physicians surveyed by Encuity, 45% intended to change their breast cancer treatment plan once Genentech’s T-DM1 becomes available, while 44% intended to increase their use of Johnson & Johnson’s prostate cancer treatment, Zytiga®. Other treatments noted include Genentech’s Avastin® for the treatment of colon and ovarian cancer, as well GSK’s dabrafenib for the treatment of melanoma.
T-DM1 also captured the best overall product information ratings. Unaided, 44% of attendees surveyed ranked T-DM1 as having “the most important piece of clinical information.” This was followed by Avastin (17%), Zytiga (16%), Cephalon’s Treanda® (13%), and Bayer/Onyx’s regorafenib (12%).
The majority of physicians surveyed (86%) gave the highest overall “presentation of information” scores to T-DM1. Zytiga closely followed, earning “very or extremely valuable” ratings from 73% of the respondents.
While Genentech ranked highest in “company perception,” others with favorable product scores did not rank among the top 10 in terms of overall company performance. The majority, 83%, of ASCO-attending physicians named Genentech as the company providing the most valuable information. Novartis was second with 37% of mentions, followed by BMS, Pfizer, and Amgen. Interestingly, despite high product-related mentions, Johnson & Johnson and Bayer did not rank among the top 10.
Meanwhile, ASCO attendees recognized Seattle Genetics and Celgene as “up-and-coming” in the treatment of cancer. Unaided, 18% of physicians surveyed mentioned Seattle Genetics as an up-and-coming company in the treatment of cancer, while 17% mentioned Celgene. These were followed by Millennium, Dendreon, and Onyx.
Overall, oncologists and hematologists surveyed gave the conference high ratings for its value, and many physicians perceive the value of the ASCO conference to be growing. Two thirds of survey respondents report that they had attended the 2011 ASCO conference as well, with 74% rating this year’s event as having equal value to the previous year and 20% rating the event as having more value than before.
For participating pharmaceutical and biotech companies, perception is everything. According to data from Encuity’s Physician Meeting and Event Audit, pharmaceutical and biotech companies spent $2.9 billion on events in the past 12 months, with 11% of their budgets going to symposia like ASCO. In the overcrowded oncology marketplace, a promotional “swing and miss” at events designed to reach oncology treatment decision makers comes at great cost. To achieve the intended comprehension of clinical data and uptake of new treatment plans, it is imperative that companies measure and refine the impact of their presence at critical venues such as ASCO. Turnkey research can quickly reveal the influence of clinical information and promotional efforts on physicians’ perceptions, understanding, and intent to prescribe.
Download the ASCO Impact Report
Encuity Research—the market research and analytics subsidiary of Campbell Alliance—conducted this survey to evaluate the relevancy and effectiveness of company-sponsored clinical data and promotions. The full results of the survey are summarized in the ASCO Impact Report, which provides an encompassing view of ASCO attendees’ intent to change treatment plans, their perceptions of clinical information presented, and their ratings of information offered by pharmaceutical and biotech companies. For a full version the ASCO Impact Report, please visit http://www.encuity.com/asco.
By Dave Johnson, Vice President, Encuity Research
June 21, 2012 - 10:06 pm
Posted in Featured
0 Comments
In an effort to provide you with timely market feedback from ASCO 2012, OBR and MDOutlook Oncology Intelligence are pleased to share results from MDOutlook’s 5th Annual post-ASCO survey fielded among its global network of more than 62,000 cancer providers.
This second Quick-Poll to be published in the OBR blog explores Non-Small Cell Lung Cancer (NSCLC) & Renal Cell Carcinoma (RCC), and stay tuned to our blog in the coming weeks as we publish QuickPolls on the other tumor types as well.
Key Conclusions:
Key Conclusions:
Key Conclusions:
Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.
Submitted by Jan Heybroek, President and Robert Stephan, Sr. Director Medical Services, The Arcas Group
June 17, 2012 - 09:06 pm
Posted in Featured
0 Comments
In an effort to provide you with timely market feedback from ASCO 2012, OBR and MDOutlook Oncology Intelligence are pleased to share results from MDOutlook’s 5th Annual post-ASCO survey fielded among its global network of more than 62,000 cancer providers.
The first Quick-Poll to be published in the OBR blog explores melanoma, and stay tuned to our blog in the coming weeks as we publish QuickPolls on the other tumor types as well.
Key Conclusions:
Key Conclusions:
Key Conclusions:
Key Conclusions:
Key Conclusions:
Key Conclusions:
Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.
Submitted by Jan Heybroek, President and Robert Stephan, Sr. Director Medical Services, The Arcas Group
June 06, 2012 - 10:06 am
Posted in Featured
0 Comments
OBR readers are oncology stakeholders – oncologists and oncology focused health care professionals, pharmaceutical developers and manufacturers, investment bank analysts, consultants, and even patients too. In consideration of the OBR audience, what were the most read articles in OBR daily over the span of the annual ASCO meeting, and how does that compare to what the media thought were the big stories?
Here is a list of the most read stories on OBR daily since Saturday:
Costly Newer Drugs No Better in Breast Cancer Study
(Reuters) June 4, 2012 – A pair of newer drugs proved no better, and by some measures inferior, to the older and cheaper chemotherapy agent paclitaxel in patients with locally advanced or metastatic breast cancer, according to results of a late stage study.
read article
A Drug for Advanced Melanoma Is Found to Prolong Patients’ Lives
(New York Times) June 4, 2012 – A new type of drug prolonged the lives of patients with advanced melanoma in a clinical trial, potentially adding to a growing number of therapies for a disease that was once nearly untreatable.
read article
Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth
(Bloomberg Businessweek) June 3, 2012 – An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.
read article
J&J Scores Big With Prostate Cancer Pill
(TheStreet) June 2, 2012 – Johnson & Johnson’s Zytiga improved survival in “pre-chemo” prostate cancer patients by 33% and more than doubled the time before cancer worsened compared to control, according to results from a phase III study to be presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
read article
US FDA Rejects Merck/Ariad Sarcoma Drug
(Reuters) June 5, 2012 – U.S. drugs regulators rejected an experimental sarcoma medicine from Merck and Ariad Pharmaceuticals on Tuesday, asking for more clinical trials, Merck said.
read article
In contrast, here are the stories that our editors think made the biggest splash in the media outlets:
Bristol Immune Drug Shows Promise in Three Cancers
(Reuters) June 2, 2012 – An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells.
read article
Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth
(Bloomberg Businessweek) June 3, 2012 – An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.
read article
A Drug for Advanced Melanoma Is Found to Prolong Patients’ Lives
(New York Times) June 4, 2012 – A new type of drug prolonged the lives of patients with advanced melanoma in a clinical trial, potentially adding to a growing number of therapies for a disease that was once nearly untreatable.
read article
Ariad’s Ponatinib Shown to Aid Leukemia Patients in Study
(Bloomberg Businessweek) June 4, 2012 – Ariad Pharmaceuticals Inc. said its experimental leukemia drug ponatinib helped patients with a mutation resistant to other therapies in a study the company will use to seek approval from U.S. and European regulators.
read article
Bayer Drug Stalls Stomach Tumors After Standard Treatment
(Bloomberg Businessweek) June 4, 2012 – Bayer AG’s experimental cancer drug regorafenib delayed progression of stomach cancer in patients who weren’t benefiting from standard treatments, potentially giving doctors a third weapon to battle gastrointestinal tumors.
read article
Why the difference? Probably because OBR readership is full of people toiling in the industry everyday. Maybe the media outlets view things differently than others, or have other motives? Either way you look at it, it was a strong annual meeting this year for exciting news, data, and studies.
by Don Sharpe